Cardiovascular & Critical Care
Long COVID Study (AFTERCOR)
This international study will improve our understanding of the long-term impact of COVID-19 and enable the development of models to better predict disease progression.
Research Objectives
Status
Current
Recruitment
Closed
Study location
Wesley Research Institute, St Andrews Hospital
Study type
Investigator Initiated
Lead investigators
- A/Prof Gianluigi Li Bassi
- Professor John Fraser
About this research project
A comprehensive international long-term follow-up study data on COVID-19 ICU survivors, assessing multi-organ injury and recovery. The results will assist clinicians in the management of long-COVID following severe disease by defining high risk groups for follow-up and guiding personalised rehabilitation.
Latest News & Discoveries
Breakthrough Research Reveals Why Some Cancer Patients Respond to Immunotherapy While Others Don’t
In a groundbreaking study, Australian researchers at the Queensland Spatial Biology Centre (QSBC) have uncovered a crucial factor that determines whether patients with head and neck cancer will respond to immunotherapy - a finding that could pave the way for more effective treatments and improved survival rates.
New Research Highlights the Potential of Private Virtual Hospitals to Improve Healthcare Access
New research has revealed the immense potential of private virtual hospitals to transform healthcare delivery in Australia.
The study explores how these “hospitals without walls” can safely and effectively provide hospital-level care in patients’ homes, combining telehealth consultations, remote monitoring, and hybrid care approaches.
Wesley Research Institute’s First Coeliac Disease Webinar Series A Success
Wesley Research Institute’s inaugural Coeliac Disease Webinar Series has been met with an overwhelming response. The two-session event - one tailored for individuals living with coeliac disease and the other for clinicians - featured leading experts Dr James Daveson, Clinical Director of the Coeliac Research and Immune Health Program at Wesley Research Institute, and Dr Jason W. Chien, Chief Medical Officer at Mozart Therapeutics.